Ligand Pharmaceuticals Incorporated
Financials
Valuation Metrics
Ligand Pharmaceuticals Incorporated's Market Cap is $5.85B. At end of 2025 it was $3.73B. Ranked #1284 of 3,112 in US market (top 41%), #430 of 1,445 on NASDAQ (top 30%), #71 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.85B | US#1,284/3,112 Sec#71/269 |
| Revenue | $274M | US#2,596/3,112 Sec#102/269 |
| Net Income | $154M | US#1,398/3,112 Sec#49/269 |
| Total Assets | $1.53B | US#2,220/3,112 Sec#62/269 |
| Net Assets | $997M | US#1,779/3,112 Sec#64/269 |
| Employees | 47 | US#1,450/3,112 Sec#58/269 |
| Value | ||
| P/E | 38.11x | US#1,663/3,112 Sec#53/269 |
| P/B | 5.87x | US#2,292/3,112 Sec#152/269 |
| P/S | 21.32x | US#2,821/3,112 Sec#147/269 |
| EV/EBITDA | 27.85x | US#2,131/3,112 Sec#65/269 |
| FCF Yield | 2.10% | US#1,934/3,112 Sec#70/269 |
| Profitability | ||
| ROE | 15.40% | US#847/3,112 Sec#45/269 |
| ROA | 10.02% | US#452/3,112 Sec#35/269 |
| Op. Margin | 36.72% | US#287/3,112 Sec#18/269 |
| Revenue Growth | 14.09% | US#1,016/3,112 Sec#86/269 |
| Financial Health | ||
| Debt Ratio | 53.62% | US#613/3,112 Sec#143/269 |
| Total Debt | $452M | US#1,859/3,112 Sec#59/269 |
| FCF | $123M | US#1,583/3,112 Sec#57/269 |
| Cash | $115M | US#2,133/3,112 Sec#166/269 |
| Current Ratio | 21.28x | US#121/3,112 Sec#30/269 |
| Net Debt/EBITDA | 1.52x | US#1,208/3,112 Sec#55/269 |
| Performance | ||
| 1Y Return | 120.04% | US#240/3,112 Sec#67/269 |
| 1M Return | -8.61% | US#2,518/3,112 Sec#153/269 |
| From 52W High | -10.59% | US#1,089/3,112 Sec#56/269 |
| 1Y MDD | -14.07% | US#255/3,112 Sec#8/269 |
| Trading | ||
| Volume | 187,445 shares | US#2,698/3,112 Sec#253/269 |
| Trading Value | $54M | US#1,301/3,112 Sec#77/269 |
| Per Share | ||
| EPS | $6.31 | US#499/3,112 Sec#17/269 |
| BPS | $51.57 | US#403/3,112 Sec#10/269 |
Company Info
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.